Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Analysis of Cell-free DNA (cfDNA) in Men With Elevated PSA Levels

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2016 by Chronix Biomedical Corporation
Sponsor:
Collaborators:
Smerud Medical Research International AS
Vanderbilt University
Information provided by (Responsible Party):
Chronix Biomedical Corporation
ClinicalTrials.gov Identifier:
NCT02771769
First received: May 10, 2016
Last updated: May 11, 2016
Last verified: May 2016
  Purpose
This is a multi-centre prospective study in which blood samples will be taken from 1500 male patients aged between 21-80 scheduled for prostate biopsy. Analysis of cell-free cancer DNA extracted from these samples will be undertaken to determine whether copy number instability scores derived from the cfDNA correlates with PSA screening levels and prostate biopsy results (i.e. Gleason score) in these patients.

Condition Intervention
Prostatic Neoplasms
Other: blood draw

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Multi-center Prospective Study to Analyze Cancer-derived Cell-free DNA (cfDNA) in Men With Elevated PSA Levels

Resource links provided by NLM:


Further study details as provided by Chronix Biomedical Corporation:

Primary Outcome Measures:
  • CNI correlation with biopsy [ Time Frame: Through completion of study and all data analysis which may take up to 2 years. ]
    To determine if copy number instability (CNI scores) derived from analysis of cell-free cancer DNA (cfDNA) in patients undergoing prostate biopsy correlates with biopsy diagnosis of prostate cancer.


Secondary Outcome Measures:
  • CNI correlation with BPH [ Time Frame: Through completion of study and all data analysis which may take up to 2 years. ]
    To determine if copy number instability (CNI scores) derived from analysis of cell-free DNA (cfDNA) in patients undergoing prostate biopsy can distinguish between biopsy diagnosis of benign prostatic hyperplasia (BPH) and prostate cancer.

  • CNI correlation with PIN [ Time Frame: Through completion of study and all data analysis which may take up to 2 years. ]
    To determine if copy number instability (CNI scores) derived from analysis of cell-free DNA (cfDNA) in patients undergoing prostate biopsy correlates with measured evidence of prostatic intraepithelial neoplasia (PIN).


Biospecimen Retention:   Samples With DNA
Cell-free and cell-associated DNA will be obtained from plasma and peripheral blood mononuclear cells, respectively. DNA will be stored until study is completed and data are published.

Estimated Enrollment: 1500
Study Start Date: January 2016
Estimated Study Completion Date: January 2018
Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)
Intervention Details:
    Other: blood draw
    Participants will have a venous blood draw of ~20mLs before prostate biopsy. The biopsy will then be performed and histologically graded for any malignancy present. This grade will be statistically analyzed with respect to the Copy Number Instability (CNI) determined from the results of the molecular examination of the cell-free DNA in the blood.
Detailed Description:

The prostate is the most common site of cancer in men with 240,000 new cases diagnosed annually in the United States with approximately 28,000 yearly deaths. Prostate screening typically relies on digital rectal exam (DRE) and prostate specific antigen (PSA) levels. Limitations of the PSA test include its low sensitivity and low specificity and its inability to distinguish between low-grade and high-grade lesions. Recent screening trials suggest that PSA-based screening programs result in small or no reduction in mortality, and have significant treatment-related adverse events (AEs). Better serum/plasma biomarkers are needed to supplement the PSA test in the diagnosis and management of a disease with a multiplicity of presentations and clinical outcomes.

Cancer-derived DNA present in peripheral blood (referred to as cell-free DNA or cfDNA) was first reported in 1948, but research into this area remained in a dormant state for over 50 years. Over the last ten years however, the development of Next Generation Sequencing (NGS) using massive parallel arrays has allowed researchers to create a database robust enough to distinguish normal genomic from non-diploid cfDNA. In 2008, fetal trisomy of chromosome 21 was detected by analyzing cfDNA in maternal blood. Since then, the method has been validated for trisomy 13, 18, and 21 as a clinical laboratory procedure with remarkable accuracy >99%. Recently, cancer derived cfDNA has been demonstrated to recapitulate genomic tumor DNA. Current clinical acceptance of the utility of cfDNA in cancer diagnosis has been demonstrated in multiple abstracts at the 2014 and 2015 ASCO meetings in Chicago.

In a recent publication in Clinical Chemistry, researchers at Vanderbilt University, Gottingen, Germany, and at the University of Toronto, Canada, analyzed cfDNA in the bloodstream from healthy controls as compared to those with clinically diagnosed prostate cancer. The results of this study demonstrated that it is possible to distinguish prostate cancer from healthy controls without prior knowledge of the genetic signature of the tumors and with over three times the sensitivity of the FDA-approved blood test for prostate cancer (i.e., prostate-specific antigen (PSA)). The study examined serum from more than 200 subjects with prostate cancer and more than 200 controls. The comparative data included PSA levels and prostate tissue biopsy grading (referred to as the Gleason score). The technique distinguished prostate cancer from normal controls with 84% accuracy and cancer from benign hyperplasia and prostatitis with an accuracy of 91%. Because the method quantifies the inherent chromosomal instability of cancer and can be followed as a function of time (without having to do an invasive tissue biopsy), it is called a "liquid biopsy." This multi-centre clinical study will analyze cfDNA from subjects scheduled for prostate biopsy and is designed to validate the results obtained in the above-mentioned retrospective study. If validated, the prostate cfDNA determination test will provide a non-invasive test to aid in the diagnosis of prostate cancer, as well as provide guidance on whether a biopsy should be performed.

With regard to the study procedures used, the study subject will undergo routine venipuncture and ~20 millilitres of blood (approximately 2 tablespoons) will be collected. The blood will then be processed by the Sponsor's laboratory and sent to the Sponsor's testing facility in Gottingen, Germany.

  Eligibility

Ages Eligible for Study:   21 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Male subjects between the ages of 21-80 who are scheduled for a prostate biopsy and meet one of the eligibility criteria listed below.
Criteria

Inclusion Criteria:

  1. Who, in the opinion of the site Investigator, have an abnormal PSA level as measured by a CLIA certified laboratory or non-USA equivalent within the last 60 days, and/or
  2. Who, in the opinion of the site Investigator, have an abnormal digital rectal examination

Exclusion Criteria:

  1. Male subjects with active or historical histologically confirmed diagnosis of malignancy
  2. Male subjects who have participated in a clinical trial involving an investigational drug within the 28 days prior to signing the informed consent form
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02771769

Contacts
Contact: Jessica B Collins, BA 1-615-343-6485 jessica.collins@vanderbilt.edu
Contact: David A McKeel, BA 1-615-343-6485 david.a.mckeel@vanderbilt.edu

Locations
United States, Maryland
University of Maryland Cancer Center Recruiting
Baltimore, Maryland, United States, 21201
Contact: Michele Besche, BSN, OCN    410-328-8610    mbesche@umm.edu   
Principal Investigator: Arif Hussain, MD         
United States, Tennessee
Vanderbilt University Medical Center Recruiting
Nashville, Tennessee, United States, 37212
Contact: Jessica B Collins, BA    615-343-6485    jessica.collins@vanderbilt.edu   
Contact: David A McKeel, BS    1-615-343-6485    david.a.mckeel@vanderbilt.edu   
Principal Investigator: David F Penson, MD, MPH         
Sponsors and Collaborators
Chronix Biomedical Corporation
Smerud Medical Research International AS
Vanderbilt University
Investigators
Principal Investigator: David F Penson, MD Vanderbilt University
  More Information

Publications:
Responsible Party: Chronix Biomedical Corporation
ClinicalTrials.gov Identifier: NCT02771769     History of Changes
Other Study ID Numbers: CHX-2015-01
Study First Received: May 10, 2016
Last Updated: May 11, 2016
Individual Participant Data  
Plan to Share IPD: Yes
Plan Description: Participants may request data upon writing to their physician. Data will not be available until after publication of data.

Keywords provided by Chronix Biomedical Corporation:
cell-free DNA
copy number instability
liquid biopsy
cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases

ClinicalTrials.gov processed this record on May 25, 2017